(Q44768849)

English

Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury

scientific article published in January 2004

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

ChEBI release 2020-05-28

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Keith C Hayes

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Patrick J Potter

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Jane T Hsieh

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Mitchell A Katz

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Andrew R Blight

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Ron Cohen

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Archives of Physical Medicine and Rehabilitation

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

85

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

29-34

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

The current status of studies of aminopyridines in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Pharmacokinetics of an Immediate‐Release Oral Formulation of Fampridine (4‐Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Intravenous infusion of 4-AP in chronic spinal cord injured subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Aminopyridines and the treatment of spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

International Standards for Neurological and Functional Classification of Spinal Cord Injury. American Spinal Injury Association

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0003-9993%2803%2900651-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0003-9993(03)00651-8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44768849&oldid=2143734739"